This study shows a sample of patients representative for the Eastern European population, and the impact of the treatment with SGLT-2i and GLP-1 RAs in real-life practice, that can be added to the current literature, emphasizing the real-world efficacy and response over time of administering new classes to T2DM patients regarding glycemic and weight reduction. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.